Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Astria Therapeutics in a research report issued to clients and investors on Tuesday, March 11th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will post earnings per share of ($0.50) for the quarter. HC Wainwright has a "Buy" rating and a $16.00 price target on the stock. The consensus estimate for Astria Therapeutics' current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Astria Therapeutics' Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.02) EPS and FY2026 earnings at ($1.87) EPS.
Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last released its earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.01.
ATXS has been the subject of several other reports. Wedbush reiterated an "outperform" rating and set a $28.00 price target (up from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th. Citizens Jmp upgraded Astria Therapeutics to a "strong-buy" rating in a report on Friday, January 31st. Finally, JMP Securities assumed coverage on Astria Therapeutics in a report on Friday, January 31st. They issued an "outperform" rating and a $26.00 target price for the company. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $26.67.
Get Our Latest Analysis on ATXS
Astria Therapeutics Trading Up 0.2 %
NASDAQ:ATXS traded up $0.01 on Friday, hitting $6.49. 368,454 shares of the company's stock traded hands, compared to its average volume of 453,733. The company has a market cap of $366.26 million, a PE ratio of -3.11 and a beta of 0.69. Astria Therapeutics has a 1 year low of $5.73 and a 1 year high of $16.90. The firm has a 50-day moving average price of $7.10 and a 200-day moving average price of $9.46.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. increased its position in shares of Astria Therapeutics by 152.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 314,265 shares of the biotechnology company's stock valued at $3,460,000 after purchasing an additional 189,727 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Astria Therapeutics during the third quarter valued at approximately $613,000. FMR LLC increased its position in shares of Astria Therapeutics by 29.2% during the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company's stock valued at $86,123,000 after purchasing an additional 1,767,714 shares during the period. Barclays PLC increased its position in shares of Astria Therapeutics by 70.5% during the third quarter. Barclays PLC now owns 92,651 shares of the biotechnology company's stock valued at $1,020,000 after purchasing an additional 38,321 shares during the period. Finally, Vestal Point Capital LP increased its position in shares of Astria Therapeutics by 23.1% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company's stock valued at $44,040,000 after purchasing an additional 750,000 shares during the period. 98.98% of the stock is currently owned by institutional investors and hedge funds.
About Astria Therapeutics
(
Get Free Report)
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
Read More
Before you consider Astria Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astria Therapeutics wasn't on the list.
While Astria Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
